DROSPIRENONE vs. NUVARING – SIDE EFFECTS COMPARISON

NUVARING VAGINAL RING LAWSUITS SIMILAR TO YAZ YASMIN LAWSUITS OVER BLOOD CLOT RISKS AND SIDE EFFECT CONCERNS
NUVARING
is a VAGINAL RING that is left in the vagina for three weeks. It acts as a contraceptive by releasing hormones that inhibit the reproductive process and prevent pregnancy. The DROSPIRENONE (DRSP) containing family of contraceptives are oral contraceptive pills that also release hormones to prevent pregnancy. Both represent a ‘new’ form of birth control and have been linked to blood clots that can form in the veins or arteries. A blood clot can prove to be fatal or life threatening if undetected or untreated because it can travel into the heart, lungs or brain causing life altering injuries or disabilities.

NUVARING BLOOD CLOT RISK IS 90% HIGHER THAN OTHER HORMONAL CONTRACEPTIVES.

A May 2012 study, published in the British Medical Journal, links NUVARING VAGINAL RINGS to higher risks of blood clots and draws comparisons to DROSPIRENONE (DRSP) containing birth control pills.

NUVARING RISK OF BLOOD CLOTS COMPARED TO DROSPIRENONE (DRSP) PILLS.

In “Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10“, the authors conducted one of the first studies to consider the risk of blood clots from use of NUVARING VAGINAL RINGS. Marketed as a care free alternative to birth control pills or intrauterine devices (IUD) the study found that:

  • NUVARING VAGINAL RING users were 6.5x more likely to have experience a blood clot, or venous thrombosis, than a non-user of hormonal contraception.
  • NUVARING VAGINAL RING conferred a 90% higher risk of blood clots than contraceptives containing levonorgestrel, a risk comparable to that of DROSPIRENONE (DRSP) birth control pills.
  • Consistent with the U.S. Food & Drug Administration Study findings released in October 2011, NUVARING VAGINAL RING users were exposed to a 48% higher risk of blood clot, or venous thrombosis, than users of other hormonal contraceptives containing levonorgestrel.
Arguably, the latest study, and FDA’s findings of October 2011, make NUVARING VAGINAL RINGS and DROSPIRENONE (DRSP) containing birth control the highest risk methods of contraception on the market. They were both the subject of FDA hearings on December 8, 2011. However, the recent release of this BMJ study may help shed more light on the risk profile of both pills in comparison to other available methods of contraception. Both are the subject of Multi-District Litigation (MDL) where cases are centralized from around the United States to facilitate the progress and coordination of pre-trial activities.
FREE BLOOD CLOT CASE EVALUATIONS FOR USERS OR SURVIVORS OF NUVARING VAGINAL RINGS AND DROSPIRENONE CONTAINING BIRTH CONTROL PILLS ARE AVAILABLE THROUGH THE USE OF THE CONTACT FORM BELOW.